Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2/Neu GP2 vaccine - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology

Drug Profile

HER2/Neu GP2 vaccine - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology

Alternative Names: GLSI-100; GP2 peptide + GM-CSF vaccine; GP2 peptide - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology; HER2/Neu Peptide GP2; HER2/neu peptide vaccine

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Uniformed Services University of the Health Sciences
  • Developer Greenwich LifeSciences Inc; NuGenerex Immuno-Oncology
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 27 Feb 2024 Phase-III clinical trials in Breast cancer (Second-line therapy or greater) in Italy, France, Spain, Germany (Intradermal) (NCT05232916)
  • 22 Feb 2024 Greenwich LifeSciences holds a meeting with EMA for a marketing license application in Europe for GLSI 100
  • 14 Feb 2024 Greenwich LifeSciences plans to file a patent protection for manufacturing, pharmacy, or injection processes of HER2/Neu GP2 vaccine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top